Myeloperoxidase in the diagnosis of acute coronary syndromes: The importance of spectrum - 16/11/11
, John Nagurney, MD b, Robert Birkhahn, MD c, Adam Singer, MD d, Nathan Shapiro, MD, MPH e, Judd Hollander, MD f, Ted Glynn, MD g, Richard Nowak, MD h, Basmah Safdar, MD i, Chadwick Miller, MD j, Mary Peberdy, MD k, Francis Counselman, MD l, Abhinav Chandra, MD m, Joshua Kosowsky, MD n, James Neuenschwander, MD o, Jon Schrock, MD p, Stephen Plantholt, MD q, Elizabeth Lewandrowski, PhD, MPH b, Vance Wong, PhD r, Ken Kupfer, PhD r, Deborah Diercks, MD sRésumé |
Background |
Myeloperoxidase (MPO) is proposed for risk stratification in patients with suspected acute coronary syndromes (ACSs). We determined if MPO has diagnostic value in patients being evaluated for ACS.
Method |
MIDAS was an 18-center prospective study enrolling suspected ACS emergency department patients who presented <8 hours after symptom onset and in whom serial cardiac markers and objective cardiac perfusion testing were planned. Blinded MPO (Biosite, Inc, San Diego, CA) and troponin I (Triage Cardio 3; Biosite, Inc) were drawn at arrival, and Troponin I (TnI) was measured at 90, 180, and 360 minutes. Final diagnoses were adjudicated by the local investigator blinded to study assay.
Results |
Of 1,018 patients, 54% were male, 26% black, with a mean age of 58 ± 13 years. Diagnoses were ACS in 288 (23%) and noncardiac chest pain (NCCP) in 788 (77%). Of patients with ACS, 94 (9.2%) had a myocardial infarction (MI) at presentation (69 non–ST-elevation MI, 25 ST-elevation MI), and 136 had unstable angina. Using a cutpoint of 210 ng/mL to provide 90% specificity, MPO had a sensitivity of 0.18; negative predictive value, 0.69; positive predictive value, 0.47; negative likelihood ratio, 0.91; and a positive likelihood ratio of 1.83 to differentiate ACS and NCCP. Because of the large overlap of quartiles, MPO was not clinically useful to predict serial TnI changes. The C statistics ± 95% CI for MPO differentiating ACS from NCCP and for AMI versus NCCP were 0.629 ± 0.04 and 0.666 ± 0.06, respectively.
Conclusions |
Myeloperoxidase has insufficient accuracy for decision making in patients with suspected ACS.
Le texte complet de cet article est disponible en PDF.Plan
| Debabrata Mukherjee, MD, served as guest editor for this article. |
|
| Reg no. NCT01134913. |
Vol 162 - N° 5
P. 893-899 - novembre 2011 Retour au numéro
Article précédent
- Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function
- Chiara Melloni, Stefan K. James, Jennifer A. White, Robert P. Giugliano, Robert A. Harrington, Kurt Huber, Pierluigi Tricoci, Paul W. Armstrong, Frans Van de Werf, Gilles Montalescot, Robert M. Califf, L. Kristin Newby
- Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
- Cono A. Ariti, John G.F. Cleland, Stuart J. Pocock, Marc A. Pfeffer, Karl Swedberg, Christopher B. Granger, John J.V. McMurray, Eric L. Michelson, Jan Östergren, Salim Yusuf
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?